Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, our results demonstrated that the enforced expression of miR-145 in H929 cells profoundly decreased the levels of p-AKT and p-PI3K, which may contribute to some extent to the inhibition of MM cell proliferation and survival.
|
25369735 |
2015 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, the novel specific PI3K/Akt/mTOR signaling inhibitor S14161 displayed its prowess as a potential therapeutic agent by targeting MM SP cells.
|
25915427 |
2015 |
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Multiple myeloma (MM) is a generally fatal plasma cell cancer that often shows activation of the phosphoinositide 3-kinase/Akt (PI3K/Akt) pathway.
|
25837824 |
2015 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show p110 α and β are the predominant PI3K catalytic subunits in MM and that a highly selective class I PI3K inhibitor, GDC-0941, has robust activity as a single agent to induce cell cycle arrest and apoptosis of both MM cell lines and patient myeloma cells.
|
23318440 |
2014 |
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cancers like multiple myeloma (MM), which display elevated activity in key translation regulatory nodes, such as the PI3K/mammalian target of rapamycin and MYC-eukaryotic initiation factor (eIF) 4E pathways, are predicted to be particularly sensitive to therapeutic strategies that target this process.
|
25197055 |
2014 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We tested the effect of pan-class I PI3K inhibition by siRNA silencing or pharmacologic inhibition with buparlisib on MM cell survival, apoptosis and cell cycle in vitro and tumor growth and mobilization of MM cells in vivo.
|
25060991 |
2014 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PI3K/Akt/mTOR signal transduction pathway plays a central role in multiple myeloma (MM) disease progression and development of therapeutic resistance. mTORC1 inhibitors have shown limited efficacy in the clinic, largely attributed to the reactivation of Akt due to rapamycin induced mTORC2 activity.
|
23185517 |
2012 |
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A transcriptional-dependent (TFEB) and independent (PI3K/mTORC1) activation of autophagy mediated FK866 MM cytotoxicity.
|
22955917 |
2012 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that oncogenic RAS is a predictor of sensitivity to combination treatment with PI3K/Akt and MEK/MAPK inhibitors and that such an approach might therefore be beneficial for this genetically well-defined subgroup of MM patients.
|
22985491 |
2012 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have identified a robust cytogenetic biomarker for response to PI3K/mTOR inhibition--these results will inform the design and prioritisation of clinical studies with novel inhibitors in genetic subgroups of myeloma.
|
22415553 |
2012 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Pim inhibitor (Z)-5-(4-propoxybenzylidene) thiazolidine-2, 4-dione and the PI3K inhibitor LY294002 cooperatively enhance MM cell death.
|
21475253 |
2011 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.
|
20505158 |
2010 |
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that PI3K/AKT mutations may not play a major role in multiple myeloma.
|
20022634 |
2010 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since PTEN-null myeloma lines exhibited much stronger Akt activation than PTEN-expressing cells in response to insulin-like growth factor I stimulation, we determined whether Akt could be responsible for PI3K-mediated cell survival and growth of PTEN-null myeloma lines.
|
13679867 |
2003 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, our results have established the role of PTEN, but not SHIP and SHIP2, in negatively regulating the PI3K/Akt cascade and in myeloma leukemogenesis.
|
12149650 |
2002 |